Showing 4311-4320 of 7365 results for "".
- Vichy Dercos Launches Advanced Scalp Line in US Markethttps://practicaldermatology.com/news/vichy-dercos-launches-advanced-scalp-solutions-us-market/2468512/Vichy Decros has announced the US launch of its new three-step system targeting scalp concerns, representing w
- Analysis: HS-Related Genetic Markers Predict Cardiometabolic Outcomeshttps://practicaldermatology.com/news/study-finds-hs-related-genetic-markers-predict-cardiometabolic-outcomes/2468406/A new cohort study suggests individuals with a high polygenic risk score (PRS) for hidradenitis suppurativa (HS) have an increased risk of developing coronary artery disease (CAD) and diabetes. Study researchers used data from 391,481 participants of European ancestry in the UK Biobank, e
- LITE: Home-Based UV-B Phototherapy Matches Office-Based Treatment in Psoriasishttps://practicaldermatology.com/news/lite-home-based-uv-b-phototherapy-matches-office-based-treatment-psoriasis/2468330/Results from a new study suggest home-based narrowband UV-B phototherapy for psoriasis is noninferior to office-based treatment in achieving clear skin and improving patient quality of life. The researchers conducted the analysis across 42 dermatology practices in the United States and inc
- IGSRT Shows High Recurrence-Free Rates in Non-Melanoma Skin Cancerhttps://practicaldermatology.com/news/igsrt-shows-high-recurrence-free-rates-non-melanoma-skin-cancer/2468185/Nonmelanoma skin cancer (NMSC) treated with Image-Guided Superficial Radiation Therapy (IGSRT) showed consistently high freedom from recurrence rates, regardless of patient age or sex, according to a new analysis. The large retrospective cohort study, published in Geriatrics and c
- Survey: Mixed Sentiments for AI in Dermatologyhttps://practicaldermatology.com/news/ai-dermatology-survey-reveals-mixed-sentiments/2467817/A national survey of U.S. dermatologists reveals both enthusiasm and concern about the potential integration of artificial intelligence chatbots (AIC) into dermatological practice. The study, published in the Journal of Drugs in Dermatology, evaluated results from an online cross-sectiona
- Analysis: Age, Number of Mohs Surgery Stages Linked with Higher-risk Basal Cell Carcinomahttps://practicaldermatology.com/news/analysis-age-number-mohs-surgery-stages-linked-higher-risk-basal-cell-carcinoma/2467270/
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- INTEGUMENT-OLE: Efficacy and Safety of Roflumilast Cream 0.15% in AD Maintained to 56 Weekshttps://practicaldermatology.com/news/integument-ole-efficacy-and-safety-roflumilast-cream-ad-maintained-56-weeks/2467010/Results from the INTEGUMENT-OLE long-term study suggested that roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) is effective and well-tolerated over a treatment period of up to 56 weeks in adults and children aged six years and older. Researchers for the open-label study
- FDA Approves New Humira Biosimilar for Multiple Inflammatory Conditionshttps://practicaldermatology.com/news/fda-approves-new-adalimumab-adbm-formulation-multiple-inflammatory-conditions/2462933/Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). According to a press release from the company, the approval enables an expansion of treatment options for chronic inflammatory diseases. This f
- FDA Issues Alert for Counterfeit Botox Across Multiple U.S. Stateshttps://practicaldermatology.com/news/fda-issues-alert-counterfeit-botox-across-multiple-us-states/2462747/The U.S. Food and Drug Administration (FDA) has issued an alert regarding counterfeit botulinum toxin that has been detected in several states. The agency issued a statement on April 16 noting that it is aware of the issue and is working with the Centers for Disease Control (CDC), state